SEMAGLUTIDE (GLP-1) DRUGS
Semaglutide is a type of medication known as a GLP-1 receptor agonist, initially developed to manage type 2 diabetes. GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone in the body that helps regulate appetite, blood sugar, and insulin secretion. Semaglutide mimics this hormone, leading to enhanced insulin production when blood sugar is high, reduced glucagon secretion, slower gastric emptying, and increased feelings of fullness.
These combined effects contribute significantly to weight loss. By reducing appetite and food intake, Semaglutide enables individuals to consume fewer calories without the same level of hunger, making it easier to sustain a calorie deficit. It is not a stimulant and does not cause jitters, making it a safe option for long-term use when prescribed appropriately.
POPULAR BRANDS
AND COMPARISONS
OZEMPIC
Administered as a once-weekly subcutaneous injection, Ozempic is primarily approved for type 2 diabetes management. It helps lower blood sugar and reduces the risk of major cardiovascular events. Though not officially approved for weight loss, many patients experience significant weight reduction.
WEGOVY
A higher-dose version of Semaglutide specifically approved for chronic weight management in adults with obesity or overweight conditions. Also delivered as a once-weekly injection, it reaches a maintenance dose of 2.4 mg.
RYBELSUS
The only oral version of Semaglutide, taken daily. It is designed for individuals who prefer not to inject. While effective for managing blood sugar, weight loss results may be less pronounced.
COMPARISON TABLE
| Brand | Form | Indication | Typical Dose | Key Benefit |
| Ozempic | Injection | Type 2 Diabetes | 0.5 mg – 1 mg/week | Blood sugar & CV risk |
| Wegovy | Injection | Weight Management | Up to 2.4 mg/week | Substantial weight loss |
| Rybelsus | Oral | Type 2 Diabetes | 7 mg – 14 mg/day | Non-injection option |
CLINICAL STUDIES
AND EFFECTIVENESS
Semaglutide’s effectiveness has been confirmed in multiple large-scale clinical trials:
STEP TRIALS (OZEMPIC)
A series of studies showing an average of 15-20% body weight loss in adults with obesity when used alongside lifestyle changes.
SUSTAIN TRIALS (WEGOVY)
Demonstrated effective blood sugar control and significant weight loss in patients with type 2 diabetes. Some trials also showed cardiovascular benefits.
PIONEER TRIALS (RYBELSUS)
Highlighted the efficacy of the oral form of Semaglutide for improving HbA1c and promoting moderate weight loss.
These studies also noted improvements in blood pressure, cholesterol levels, and insulin sensitivity.
DOSAGE & GUIDELINES
DOSAGE
GUIDELINES
- Semaglutide is typically started at a low dose and gradually increased to minimise side effects.
- Always follow the prescribing doctor’s instructions closely.
COMMON
SIDE EFFECTS
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Headache
SERIOUS
RISKS
- Risk of thyroid
- C-cell tumours
- Pancreatitis
- Gallbladder issues
- Kidney function concerns
MEDICAL
GUIDANCE
- Not suitable for individuals with type 1 diabetes or during pregnancy.
- Periodic monitoring of blood sugar and kidney function is recommended.
- Use in conjunction with diet and physical activity.
FAQs & EXPERT INSIGHTS
How quickly does Semaglutide work for weight loss?
Many users start noticing weight loss within the first 4-8 weeks. Maximum benefits are seen after several months.
Do I need to be diabetic to use it?
No. Wegovy is specifically approved for weight management in non-diabetic individuals.
What happens if I stop using Semaglutide?
Weight regain is common if lifestyle changes aren’t maintained.
Can Semaglutide be used with other weight loss drugs?
This is not typically recommended unless under specialist supervision.
EXPERT INSIGHT
”Semaglutide has revolutionised our approach to obesity. It’s not a magic bullet, but when combined with behavioural changes, it’s a powerful tool.
Dr. Michael Davidson:Semaglutide Expert